Year: 2019

CGG Announces Largest OBN Multi-Client Survey in UK CNSParis, France – 19 November, 2019CGG announced today a program to deliver the largest OBN multi-client survey ever conducted in the UK Central North Sea (CNS). Planned to start in early 2020, the survey has already received significant industry interest and is being prefunded in part by BP. First results are targeted for Q1 2021.In the CNS, where complex salt diapirism has created significant challenges to imaging deeper reservoir targets, this new survey, with its long-offset, full-azimuth coverage and good low-frequency signal in a shallow water environment, together with CGG’s advanced imaging technology, will provide a step-change in seismic image and reservoir characterization quality. In the first phase of this multi-year program, CGG aims to acquire over 2,000 sq. km of OBN...

CGG annonce la plus grande étude OBN multi-clients jamais réalisée dans la partie centrale de la Mer du NordParis, France – le 19 novembre 2019CGG annonce ce jour la plus grande étude multi-clients jamais réalisée dans la partie centrale de la Mer du Nord (CNS) en acquisition de données sismiques de fond de mer (OBN).  Prévue de démarrer début 2020, cette étude en partie préfinancée par BP a déjà suscité un vif intérêt de la part de l’industrie. Les premiers résultats devraient être disponibles au premier trimestre 2021.Dans cette partie centrale de la mer du nord, la complexité des dômes de sel rend très difficile l’imagerie des réservoirs profonds. Grâce à de longs offsets, à une couverture azimutale complète, à l’enregistrement des basses fréquences dans des eaux peu profondes et aux technologies de traitement/’imagerie de pointe...

EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. (“Idorsia”) (SIX: IDIA) to develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast-acting and highly selective P2Y12 receptor antagonist under development, with the Antares subcutaneous QuickShot® auto injector. Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI. According to Idorsia, the product...

MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on its operational developments for the third quarter ended September 30, 2019.Filippo Petti, CEO of Celyad stated, “We have reported a steady stream of encouraging news from our pipeline throughout the third quarter and subsequent weeks, including preliminary Phase 1 data for our first-in-class, non-gene edited allogeneic CYAD-101 CAR-T product candidate, the introduction of our proprietary OptimAb manufacturing process to our autologous relapsed/refractory acute myeloid leukemia program led by CYAD-01, and CYAD-02, the acceptance of the IND application for our next-generation candidate CYAD-02,...

Press ReleaseNokia secures 49th commercial contract by fully supporting DOCOMO PACIFIC to deliver first commercial 5G in the MarianasNokia is the primary vendor for DOCOMO PACIFIC, the leading telecommunications provider in Guam and the Mariana IslandsDOCOMO PACIFIC has launched the first operational 5G network in the region for enterprise customers in the villages of Tamuning and Hagåtña using Nokia’s end-to-end 5G solution      ·The deal is Nokia’s 49th 5G commercial contract, demonstrating Nokia’s solid 5G momentum19 November 2019Espoo, Finland – Nokia, working in partnership with DOCOMO PACIFIC, is powering connectivity in Guam with the first commercial 5G service in the Marianas. This marks Nokia’s 49th 5G commercial contract.Nokia is enabling end-user (BtoB) commercial 5G services for enterprise customers on the islands of the Marianas....

Orphazyme A/SCompany announcement                                                                              No. 29/2019                                                                                                  Company Registration No. 32266355·There are currently no US FDA-approved products for NPC·Orphazyme plans to file arimoclomol in the US in H1 2020Copenhagen, Denmark, November 19, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for arimoclomol, an investigational drug for the treatment of Niemann-Pick Disease Type C (NPC).Kim Stratton, Chief Executive Officer at Orphazyme, commented, “We are delighted with FDA’s decision...

• The companies will develop a novel drug-device product combining Idorsia’s P2Y12 receptor antagonist, selatogrel, with the Antares QuickShot® auto-injector• Idorsia is preparing for a Phase 3 study to investigate the efficacy and safety of selatogrel following subcutaneous self-administration for the treatment of a suspected acute myocardial infarction (AMI) in adult patients at risk of recurrent AMIAllschwil, Switzerland – November 19, 2019Idorsia Ltd (SIX: IDIA) today announced that it has entered into a global agreement with Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) to develop a novel drug-device product combining selatogrel, Idorsia’s potent, fast-acting, reversible, and highly selective P2Y12 receptor antagonist with the Antares subcutaneous QuickShot® auto-injector.With almost 20 years of experience, Antares has a...

Pratteln, Switzerland, November 19, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces publication of the previously reported SYROS study data in prominent peer-reviewed medical journal Neuromuscular Disorders [1], demonstrating long-term efficacy with idebenone in slowing respiratory function loss in patients with Duchenne muscular dystrophy (DMD) under routine clinical care.The publication reports data collected as retrospective cohort study (SYROS) from 18 DMD patients not using glucocorticoids who were treated with idebenone (900 mg/day) under Expanded Access Programs (EAPs) after having completed the Phase III DELOS study. The objective was to assess the respiratory function evolution during periods of treatment with idebenone (‘On-Idebenone’) compared to periods without idebenone treatment (‘Off-Idebenone’) in the same patients....

Pratteln, Schweiz, November 19, 2019 – Santhera Pharmaceuticals (SIX: SANN) gibt die Publikation von bereits angekündigten SYROS-Studiendaten in der renommierten Fachzeitschrift Neuromuscular Disorders [1] bekannt. Die Daten zeigen langfristige Wirksamkeit von Idebenon bei der Verlangsamung des Atmungsfunktionsverlustes bei Patienten mit Duchenne-Muskeldystrophie (DMD) im Therapiealltag.Die Publikation stellt Daten aus einer retrospektiven Kohortenstudie (SYROS) mit 18 DMD-Patienten ohne Glukokortikoid-Behandlung vor, die nach Abschluss der Phase-III-DELOS-Studie im Rahmen von erweiterten Zugangsprogrammen (Expanded Access Programs, EAPs) mit Idebenon (900 mg/Tag) behandelt wurden. Das Ziel war der Vergleich der Atmungsfunktion in Phasen mit Idebenon-Behandlung (‘On-Idebenon‘) gegenüber Phasen ohne Idebenon-Behandlung (‘Off-Idebenon‘)...

CALGARY, Alberta, Nov. 18, 2019 (GLOBE NEWSWIRE) — Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.WT) (“Sugarbud“) is pleased to announce the completion of its previously announced non-brokered private placement for total proceeds of $925,000 (the “Private Placement“).Pursuant to the Private Placement, Sugarbud issued a total of 18,500,000 units (“Units“) of Sugarbud at a price of $0.05 per Unit. Each Unit was comprised of one common share (“Common Share“) of Sugarbud and one Common Share purchase warrant (“Warrant“). Each Warrant entitles the holder to purchase one Common Share at a price of $0.10 until November 18, 2021, subject to early expiry in the event that the 5-day volume weighted average trading price of the Common Shares equals or exceeds $0.125. The Common Shares...